Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Endo Buys US Patent For Oxymorphone From Johnson Matthey - Quick Facts

RELATED NEWS
Trade ENDP now with 
3/22/2012 8:50 AM ET

Endo Pharmaceuticals Holdings (ENDP: Quote) said it has acquired U.S. patent for oxymorphone hydrochloride, the key API in all formulations of OPANA, from Johnson Matthey plc (JMAT.L).

By acquiring Johnson Matthey's patent to the oxymorphone ingredient, which will be listed in the U.S. Food and Drug Administration's Orange Book, Endo will enjoy additional patent protection for its OPANA franchise, now through 2029.

"This patent not only covers our newly designed to be crush resistant OPANA® ER, it covers all products that include oxymorphone that are manufactured in accordance with current FDA specifications," said Julie McHugh, chief operating officer of Endo.

Click here to receive FREE breaking news email alerts for Endo Health Solutions Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While stocks moved sharply lower at the start of trading on Thursday, selling pressure waned not long after the open. The markets have subsequently seen a notable recovery attempt, as some traders look to pick up stocks at reduced levels. The major averages have climbed well off their worst levels but are currently still posting modest losses. In another upbeat sign for the U.S. housing market, the Commerce Department released a report on Thursday showing that new home sales came in well above economist estimates in the month of April. The report showed that new home sales climbed 2.3 percent to a seasonally adjusted annual rate of 454,000 in April from the revised March rate of 444,000. Consumer sentiment in the euro area increased for the sixth consecutive month in May to its strongest level since the middle of last year, preliminary data from the European Commission showed Thursday. The DG ECFIN flash estimate of the consumer confidence indicator for Eurozone came in at -21.9,...
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.